Register
Login:
Share:
Email Facebook Twitter




Sareum Share Chat (SAR)



Share Price: 0.815Bid: 0.78Ask: 0.85Change: 0.065 (+8.67%)Riser - Sareum
Spread: 0.07Spread as %: 8.97%Open: 0.79High: 0.79Low: 0.72Yesterday’s Close: 0.75


Share Discussion for Sareum


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


manxairbus321
Posts: 926
Premium Chat Member
Off Topic
Opinion:Strong Buy
Price:0.815
Summary
Today 18:21
Summary
This clinical study is looking at a new drug called CCT245737 which looks promising in laboratory studies when given
with other cancer medicines (known as chemotherapy). We now wish to find out if it will be useful in treating patients
with cancer when given with chemotherapy. The chemotherapy used in this study will either be gemcitabine plus
cisplatin or gemcitabine alone. Both of these chemotherapies are currently used as standard treatments for cancer.
CCT245737 is a type of drug called a kinase inhibitor. It blocks a chemical messenger (enzyme) called checkpoint
kinase 1 (CHK-1) which is part of the signaling process within cells which can make cells produce chemicals that
trigger and control cell growth and cell death. Chemotherapy agents are used to try to kill cancer cells however
sometimes cancer cells can repair themselves using these signaling processes and continue to grow. CCT245737
may help chemotherapy to work better by preventing cancer cells from repairing themselves, when they have been
damaged by chemotherapy, so that more cancer cells could be killed.
There are 2 stages to this study:
1)Patients in Stage 1 will be given CCT245737 in addition to receiving treatment with gemcitabine and cisplatin.
2)Patients in Stage 2 will be given CCT245737 in addition to receiving treatment with gemcitabine only.
Each stage of the study will be split into two parts: Part one will be a ‘dose escalation’ phase where groups of patients
will receive increasing doses of the CCT245737 to find the best dose to treat patients with. Part two will be an
‘expansion phase’ where a larger group of patients will be treated at the highest dose level of CCT245737 considered
to be safe from part one to find out more about how the drug is working.
 
Jackones
Posts: 21
Off Topic
Opinion:No Opinion
Price:0.815
RE: Where we at with this?
Today 17:27
I have and I was asking to see if I've understood it correctly, would it have been so hard just to answer the question haha?
manxairbus321
Posts: 926
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.815
RE: Where we at with this?
Today 17:20
Look at the RNS.
Jackones
Posts: 21
Off Topic
Opinion:No Opinion
Price:0.815
Where we at with this?
Today 16:53
Have they started treatment or still in recruitment?
manxairbus321
Posts: 926
Premium Chat Member
Off Topic
Opinion:Strong Buy
Price:0.75
RE: Sar's development chronology . ..
Today 16:30
Nice summary looking through all the info.

Fingers crossed for a productive week for us
Arbitrage
Posts: 844
Observation
Opinion:No Opinion
Price:0.75
Sar's development chronology . . .
Today 16:17
A useful opportunity (courtesy of Investegate.co.uk), to reflect upon the journey travelled by the Company, from it's inception to the present date and which in addition, also highlights the considerable number of associated commercial opportunities stemming from our various compound developments:

http://www.investegate.co.uk/Index.aspx?searchtype=3&words=sar
JonTangle
Posts: 64
Off Topic
Opinion:No Opinion
Price:0.75
Oops...
Today 10:55
That's 2015, not 2016. Sorry, need my eyes testing (seriously)!
JonTangle
Posts: 64
Off Topic
Opinion:No Opinion
Price:0.815
Press...
Today 10:44
I don't believe this has previously been posted, if it has I certainly missed it.

http://m.theboltonnews.co.uk/news/13495659.Chemotherapy_boosting_drug_tested_on_lung_and_pancreatic_cancer_patients/

Nothing new contained within it as such but hey it's PR!
stevej
Posts: 6,760
Off Topic
Opinion:No Opinion
Price:0.75
Thoth2
Sat 18:30
Some good posts recently, thank you.....




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.